RJFSA
TCRT icon

Raymond James Financial Services Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-73
Closed -$3K – 2386
2016
Q2 		$3K Hold
73
– – ﹤0.01% 2277
2016
Q1 		$8K Buy
+73
New +$74.7K ﹤0.01% 2063

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Raymond James Financial Services Advisors's TCRT Position: Q3 2023 in Review

Raymond James Financial Services Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2023, closing a stake of 97 shares — an estimated $7.43K sold.

Raymond James Financial Services Advisors first reported a position in TCRT in Q3 2015 and held it in 30 quarters. The position peaked at $1.54M in Q4 2015. 89 funds tracked by Wall St. Rank hold TCRT as of Q3 2023.

  • Raymond James Financial Services Advisors reported no remaining Alaunos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 97 Alaunos Therapeutics shares in Q3 2023, an estimated $7.43K.
  • Raymond James Financial Services Advisors first reported a position in Alaunos Therapeutics in Q3 2015 and held it in 30 quarters.
  • Raymond James Financial Services Advisors's Alaunos Therapeutics position peaked at $1.54M in Q4 2015.
  • 89 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.